U.S. Markets close in 3 hrs 17 mins

Array BioPharma Inc. (ARRY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.87-0.15 (-1.63%)
As of 12:43PM EDT. Market open.
People also watch

Array BioPharma Inc.

3200 Walnut Street
Boulder, CO 80301
United States

Full Time Employees177

Key Executives

Mr. Ron Squarer BSc (Biochemistry), MBAChief Exec. Officer and Director1.06MN/A50
Mr. Andrew R. RobbinsChief Operating Officer684.38kN/A41
Mr. John R. MooreVP, Gen. Counsel and Sec.576.4kN/A53
Dr. Victor Sandor M.D., C.MChief Medical Officer745.35kN/A51
Mr. Jason HaddockChief Financial OfficerN/AN/A47
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, and Selumetinib for the treatment of cancer, as well as ASC08/Danoprevir, a protease inhibitor for hepatitis C virus. Its drug candidates in Phase II clinical trials comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASLAN001/Varlitinib, a pan-HER2 inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; Prexasertib/LY2606368, a chk-1 inhibitor for cancer; LOXO-101, a PanTrk inhibitor for cancer; and ONT-380/ARRY-380, an HER2 inhibitor for breast cancer. The company’s Phase I drugs include GDC-0994, an ERK inhibitor for cancer; and ARRY-382, a CSF1R inhibitor for cancer, as well as Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer. It has a clinical trial collaboration agreement with Merck to investigate the safety and efficacy of the company’s MEK inhibitor, binimetinib, with Merck's anti-PD-1 therapy, KEYTRUDA in metastatic colorectal cancer patients with microsatellite stable tumors; and a clinical research collaboration with Bristol-Myers Squibb to investigate the safety, tolerability and efficacy of Array’s investigational MEK inhibitor, binimetinib. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.

Corporate Governance

Array BioPharma Inc.’s ISS Governance QualityScore as of June 2, 2017 is 8. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.